without the need to monitor activated partial thromboplastin time. Beginning, in 1993, the Food and Drug Administration approved LMWH for prophylaxis of deep vein thrombosis (DVT) and prophylaxis for ischemic complications of unstable angina/non-Q wave myocardial infarction. Nevertheless, neurosurgeons remained perturbed by the new chemoprophylactic agent in a postoperative regimen. is manuscript presents the first meta-analyses of studies that directly compare prophylactic LMWH to prophylactic UFH in neurosurgery with the primary outcome measures: venous thromboembolism (VTE) and complications.
MATERIALS AND METHODS
is study was registered à priori in our institution's Library Protocol for Systematic Reviews. Per this protocol, all citations were collected by a trained reference analyst with a Master of Library and Information Science and a designation by the Academy of Health Information Professionals. e analyst must follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in the Enhancing the QUAlity and Transparency Of health Research resources, in which a systematic review identified relevant studies through a computer-aided search of American articles (MEDLINE from 1946 to July 17, 2017) and European articles (EMBASE 1947-July 17, 2017) [ Figure 1 ]. e following key words provided sensitivity inclusive of all types of neurosurgical procedures with postoperative chemoprophylaxis: "neurosurgery" and any of its possible endings, "spine" and any of its possible endings, "brain neoplasm" in addition to "prophylaxis" and any of its possible endings, as well as heparin, dalteparin, enoxaparin, Lovenox, and nadroparin. is technique also ensured that citations in the spine subspecialty were not overlooked in orthopedic literature. e references within literature reviews and systematic reviews generated by the computer-aided search were also scrutinized for relevant studies. Only publications that directly compared the efficacy of prophylactic doses of LMWH versus UFH were included in the study. Due to the abundance of literature comparing prophylactic heparin to placebo, studies that did not complete a head-to-head comparison of the two heparin derivatives were excluded from this review. Resources on therapeutic doses of heparin products address topics outside the scope of this analysis and were, thus, excluded from the study. Manuscripts on nonhuman subjects and in languages other than English were similarly excluded from the study. e primary outcomes measure includes incidence of VTE on prophylactic doses of LMWH versus UFH. Secondary outcome measures explored suspected adverse events secondary to chemoprophylaxis. Minor complications were limited to active, noncranial bleeding diathesis, as evidenced by an unexpected decline in hemoglobin/hematocrit. Major complications were defined as other hemorrhagic complications. Data were extracted from the articles by two independent reviewers. ree articles met the inclusion and exclusion criteria [ Table 1 ]. Postoperative VTE chemoprophylaxis with LMWH compared to UFH was compared with summary statistics, reporting means ± standard deviations or frequencies/ percentages. Binary outcomes were compared using a Chisquare test. Continuous outcomes were compared with t-test. [9] As detailed in the materials and methods section of a meta-analysis on prophylactic heparin in neurosurgery by Iorio and Agnelli, each group treated with prophylactic LMWH was compared with prophylactic UFH. [7] e primary outcome measures (observed minus expected number of events, O-E) and its variance (V[O-E]) were calculated for each trial. e data from the individual studies were then pooled following the fixed effects model using the Mantel and Haenszel method. Briefly, the overall odds of the outcome measure and its variance follow:
Where, n equals the number of patients treated, d equals the number of patients with the event, and N equals the total number of patients in the trial. Two-tailed P values were calculated from the 95% confidence intervals (CIs) from the individual studies and the overall odds ratio (OR). e data from the three studies were illustrated on a forest plot. To emphasize larger studies, the size of the squares is proportional to variance (V[O-E]).
Since the evaluation of VTE was determined heterogeneously (i.e., 100 µCi of 125 I-labeled fibrinogen, phlebography, and/ or duplex venous ultrasonography) in each of the three publications, the efficacy of prophylactic LMWH was ascertained from the per-protocol analysis. Safety, on the other hand, was assessed by the intention-to-treat analysis. e heterogeneity (I 2 ) of the studies was tested with the χ 2 statistic.
RESULTS
Of a search through 156 articles, three studies met the aforementioned inclusion and exclusion criteria for the current meta-analysis [ Figure 1 ]. Chemoprophylaxis of UFH versus LMWH following a spine operation was found in only one study [11] and the following cranial operations in two studies [5, 8] [ Table 1 ]. A total of 429 patients were pooled to calculate the incidence of VTE and suspected chemoprophylaxis-related complications.
VTE
Within each individual study, the Chi-square comparisons of the incidences of VTE between LMWH and UFH chemoprophylaxis cohorts did not reach statistical significance [ Table 1 ]. In total, the pooled incidence of postoperative VTE culminated in 5.6% (12/213) after LMWH chemoprophylaxis versus 3.7% (8/216) after UFH chemoprophylaxis (P = 0.343).
According to the forest plot in Figure 2 , the overall odds of VTE did not statistically significantly differ following postoperative LMWH compared to UFH chemoprophylaxis (OR = 1.42, 95% CI 0.62-3.75, P = 0.308). No significant heterogeneity with respect to VTE events was observed among the three articles (I 2 = 15.1%, P = 0.308). Notably, Voth et al. only measured the incidence of deep VTE, not pulmonary embolism. [11] Goldhaber et al. noted that only one patient with a deep VTE developed a pulmonary embolism in UFH group. [5] No pulmonary emboli were observed in the study by Macdonald et al. [8] 
Suspected chemoprophylaxis-related complications
In all three publications in the present meta-analysis, minor complications were uniformly defined as drops in postoperative hemoglobin/hematocrit requiring blood transfusions. [5, 8, 11] One notable exception: Macdonald et al. prematurely withdrew two craniotomy patients from LMWH arm of the randomized trial due to thrombocytopenia. [8] e low platelet count dropped to 98,000 in a patient with a symptomatic proximal and distal DVT; the heparin-induced antiplatelet antibodies were negative. e other patients saw a platelet nadir of 86,000 without VTE events; no antibody testing was completed because the platelet count recovered on discontinuing the study drug. e other two randomized trials in this meta-analysis did not mention heparin-induced thrombocytopenia.
Within each study, the Chi-square comparisons of the incidences of minor complications between LMWH and UFH chemoprophylaxis cohorts did not reach statistical significance [ Table 1 ]. In total, the pooled incidence of postoperative minor complications was 4.7% (10/213) after LMWH chemoprophylaxis versus 4.6% (10/216) after UFH chemoprophylaxis (P = 0.974). According to the forest plot in Figure 3 , the overall odds of minor complications did not statistically significantly differ following postoperative LMWH compared to UFH chemoprophylaxis (OR = 1.01, 95% CI 0.41-2.50, P = 0.929). No significant heterogeneity with respect to minor complications was observed among the three articles (I 2 = 0.0%, P = 0.929).
Major complications encompassed all other salient adverse events. All four major adverse events included intracranial hemorrhages: three after prophylactic LMWH (1.4%) and one after prophylactic UFH (0.5%) (P = 0.992). Goldhaber et al. reported a 66-year-old female in LMWH cohort with intraventricular hemorrhage 7 days after a craniotomy for metastatic brain neoplasm (n = 1/75, 1.3%). [5] e patient was managed with an external ventricular drain (EVD) followed by a ventriculoperitoneal catheter. Although no major complications were ascertained in UFH cohort in the study by Goldhaber et al., no statistically significant differences were [8] EVD was removed on placement of a ventriculoperitoneal shunt on postoperative day 2. e patient was severely disabled at 1-month follow-up. Voth et al. did not observe any major complications and were, thus, excluded in the forest plot in Figure 4 . [11] e overall odds of major complications did not statistically significantly differ following postoperative LMWH compared to UFH chemoprophylaxis (OR = 2.32, 95% CI 0.34-16.01, P = 0.831). No significant heterogeneity with respect to major complications was observed among the three articles (I 2 = 0.0%, P = 0.831). [5, 8, 11] 
DISCUSSION
In a meta-analyses that focus on studies that directly compare the two heparin injections in neurosurgery, we identified three articles, whose pooled results did not yield a statistically significant difference in the rates of VTE (P = 0.343), minor complications (P = 0.974), or major complications (P = 0.559) [ Table 1 ]. Forest plot analyses similarly failed to illustrate a difference in the odds of VTE, minor complications, or major complications [ Figures 2-4 ]. ese findings corroborate a similar meta-analysis on "LMWH and UFH for the prevention of VTE in neurosurgery" by Iorio and Agnelli who explored four articles that compared either prophylactic UFH to mechanical prophylaxis only or prophylactic LMWH to mechanical prophylaxis only. [7] Unfortunately, none of the meta-analyses in the four neurosurgical studies directly compared prophylactic UFH to LMWH. Although any type of heparin prophylaxis resulted in 45% relative risk reduction of VTE events, the conclusions stated that "LMWH and UFH have been shown to be effective for prophylaxis of VTE in elective neurosurgery without excessive bleeding risk. " [7] Forest plot analyses did not demonstrate a difference in bleeding complications compared to mechanical prophylaxis only. e authors did not elaborate on direct comparisons of prophylactic UFH versus LMWH for VTE events or bleeding complications.
While the efficacy of prophylactic LMWH has been well validated in literature; [1] historically speaking, concern for hemorrhagic-related complications has discouraged neurosurgeons from using prophylactic LMWH in surgical patients. Dating back to 1998, Dickinson et al. randomized patients undergoing craniotomy for tumor to preoperative prophylactic LMWH + sequential compression devices (SCDs) to SCDs alone. [3] e study was terminated prematurely because 5 of 46 patients in the former group sustained postoperative intracranial hemorrhages. However, these alarming outcomes have been questioned because (A) chemoprophylaxis was initiated before surgery, and (B) no direct comparisons of prophylactic LMWH to UFH were included in the study. In a systematic review and meta-analysis on VTE prophylaxis in neurosurgical patients, Hamilton et al. wrote "intracerebral hemorrhage was more common in those receiving heparin (prophylactic UFH or LMWH), but not statistically significantly. " [6] In a prospective study of 1319 major intracranial procedures and 1504 minor intracranial procedures (e.g., shunts and biopsies) by Gerlach et al., prophylactic LMWH was started within 24 h of surgery. [4] e postoperative hemorrhage rate for major intracranial procedures and minor intracranial procedures was 3.2% and 0.07%, respectively, leading the author to "support the concept of postoperative pharmacological thromboembolic prophylaxis in patients undergoing intracranial surgery. " To that end, the Journal of Neurooncology published a systematic review of perioperative thromboprophylaxis in patients with craniotomy for brain tumors titled, "e addition of enoxaparin starting the day after surgery, significantly reduces clinically manifest VTE, despite an increase in major bleeding events. " [10] With respect to prophylactic UFH in neurosurgery, Cerrato et al. randomly assigned 100 patients undergoing elective neurosurgery to half with UFH and half to control. [2] No statistically significant differences were elucidated in postoperative blood transfusion, decline in hemoglobin, and hematomas. ese recommendations help to illustrate the efficacy of prophylactic LMWH or UFH, with an acceptable safety profile in neurosurgery.
Limitations
Although the tests for heterogeneity (I 2 ) in the set metaanalysis did not reach statistical significance for all three outcome measures -VTE episodes (I 2 = 15.1%, P = 0.308), minor complications (I 2 = 0.0%, P = 0.929), and major complications (I 2 = 0.0%, P = 0.831) -all three studies utilized different doses of prophylactic LMWH. However, the frequency of injections was limited to once daily, whereas the dose and frequency of prophylactic UFH remained constant across all three studies.
is meta-analysis is also subject to a selection bias because the tight inclusion and exclusion criteria led to a review of only three studies. As such, a relatively small number of 429 patients were entered into the pooled analysis, which may limit our ability to detect a statistically significant difference between LMWH and UFH. Further, randomized clinical trials comparing prophylactic LMWH versus UFH are required to elucidate superior safety and efficacy in neurosurgical patients.
CONCLUSION
is is a meta-analysis of studies that directly compare prophylactic LMWH to UFH in neurosurgery. Prophylactic doses of both LMWH and UFH equally prevented VTE after neurosurgical operations. LMWH, compared to UFH, did not statistically significantly increase the odds of minor or major complications. While these results preliminarily suggest similar profiles of both chemoprophylactic heparin injections, further, randomized clinical trials comparing prophylactic LMWH versus UFH are required to elucidate superior safety and efficacy in neurosurgical patients.
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